• 1
    Munoz N,Bosch FX,de Sanjose S,Herrero R,Castellsague X,Shah KV,Snijders PJ,Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study Groupl. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 2
    IARC Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses. International Agency for Research on Cancer. Vol. 90. Geneva, Switzerland: WHO press, 2007.
  • 3
    Smith JS,Lindsay L,Hoots B,Keys J,Franceschi S,Winer R,Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 62132.
  • 4
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890907.
  • 5
    Snijders PJ,Steenbergen RD,Heideman DA,Meijer CJ. HPV- mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 15264.
  • 6
    Arbyn M,Sasieni P,Meijer CJ,Clavel C,Koliopoulos G,Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006; 24 ( Suppl 3): S78S89.
  • 7
    Bulk S,Bulkmans NW,Berkhof J,Rozendaal L,AJ PB,Verheijen RH,Snijders PJ,Meijer CJ. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 2007; 121: 3617.
  • 8
    Ronco G,Segnan N,Giorgi-Rossi P,Zappa M,Casadei GP,Carozzi F,Dalla Palma P,Del Mistro A,Folicaldi S,Gillio-Tos A,Nardo G,Naldoni C, et al. New Technologies for Cervical Cancer Working Group. Human Papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 76574.
  • 9
    Ronco G,Giorgi-Rossi P,Carozzi F,Dalla Palma P,Del Mistro A,De Marco L,de Lillo M,Naldoni C,Pierotti P,Rizzolo R,Segnan N,Schincaglia, et al. New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 54755.
  • 10
    Mayrand MH,Duarte-Franco E,Rodrigues I,Walter SD,Hanley J,Ferenczy A,Ratnam S,Coutlée F,Franco EL,Canadian Cervical cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 157988.
  • 11
    Cuzick J,Clavel C,Petry KU,Meijer CJ,Hoyer H,Ratnam S,Szarewski A,Birembaut P,Kulasingam S,Sasieni P,Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095101.
  • 12
    Schiffman M,Khan MJ,Solomon D,Herrero R,Wacholder S,Hildesheim A,Rodriguez AC,Bratti MC,Wheeler CM,Burk RD,PEG Group, ALTS Group. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 14750.
  • 13
    Stoler MH,Castle PE,Solomon D,Schiffman M,American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007; 127: 3357.
  • 14
    Hesselink AT,van Ham MAPC,Heideman DAM,Groothuismink ZMA,Rozendaal L,Berkhof J,van Kemenade FJ,Massuger LAFG,Melchers WJG,Meijer CJLM,Snijders PJF. Comparison of GP5+/6+-PCR and SPF10- line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008; 46: 321521.
  • 15
    Hesselink AT; van den Brule AJC; Brink AATP; Berkhof J; van Kemenade FJ; Verheijen RHM; Snijders PJF. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer Cytopathology 2004; 102: 1118.
  • 16
    Gravitt PE,Burk RD,Lorincz A,Herrero R,Hildesheim A,Sherman ME,Bratti MC,Rodriguez AC,Helzlsouer KJ,Schiffman M. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer. Epidemiol Biomarkers Prev 2003; 12: 47784.
  • 17
    Naucler P,Ryd W,Tornberg S,Strand A,Wadell G,Elfgren K,Radberg T,Strander B,Forslund O,Hanson BG,Rylander E,Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 158997.
  • 18
    Bulkmans N,Berkhof J,Rozendaal L,van Kemenade F,Boeke A,Bulk S,Voorhorst FJ,Verheijen RH,van Groningen K,Boon ME,Ruitinga W,van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 176472.
  • 19
    Ronco G,Giorgi-Rossi P,Carozzi F,Confortini M,Dalla Palma P,Del Mistro A,Gillio-Tos A,Minucci D,Naldoni C,Rizzolo R,Schincaglia P,Volante R, et al. New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492501.
  • 20
    Sherman ME,Lorincz AT,Scott DR,Wacholder S,Castle PE,Glass AG,Mielzynska-Lohnas I,Rush BB,Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 4652.
  • 21
    Castle PE,Schiffman M,Burk RD,Wacholder S,Hildesheim A,Herrero R,Bratti MC,Sherman ME,Lorincz A. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002; 11: 13949.
  • 22
    Hesselink AT,Bulkmans NW,Berkhof J,Lorincz AT,Meijer CJ,Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006; 44: 36805.
  • 23
    Cogliano V,Baan R,Straif K,Grosse Y,Secretan B,El Ghissassi F. WHO International Agency for Research on Cancer Monograpgh Working Group. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
  • 24
    Muñoz N,Bosch FX,Castellsagué X,Díaz M,de Sanjose S,Hammouda D,Shah KV,Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 27885.
  • 25
    Snijders PJF,Hogewoning CJA,Hesselink AT,Berkhof J,Voorhorst FJ; Bleeker MCG,Meijer CJLM. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006; 119: 11027.
  • 26
    ArbynM,AnttilaA,JordanJ,RoncoG,SchenckU,SegnanN,WienerH,DanielJ,von KarsaL, editors. European Guidelines for Quality Assurance in Cervical Cancer Screening,2nd edn. Luxembourg: Office for Official Publications of the European Communities, 2008. pp. 1291.
  • 27
    Cuzick J,Szarewski A,Cubie H,Hulman G,Kitchener H,Luesley D,McGoogan E,Menon U,Terry G,Edwards R,Brooks C,Desai M, etal. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 18716.
  • 28
    Castle PE,Wheeler CM,Solomon D,Schiffman M,Peyton CL,ALTS Group. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122: 23845.
  • 29
    Carozzi FM,Del Mistro A,Confortini M,Sani C,Puliti D,Trevisan R,De Marco L,Tos AG,Girlando S,Palma PD,Pellegrini A,Schiboni ML, et al. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol 2005; 124: 71621.
  • 30
    Jacobs MV,Snijders PJ,Voorhorst FJ,Dillner J,Forslund O,Johansson B,von Knebel Doberitz M,Meijer CJ,Meyer T,Nindl I,Pfister H,Stockfleth E, et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999; 52: 498503.
  • 31
    Tang NS,Tang ML,Chan IS. On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 2003; 22: 121733.
  • 32
    Quint WG,Pagliusi SR,Lelie N,De Villiers E-M,Wheeler CM. WHO Human Papillomavirus DNA International Collaborative Study Group. Results of the first world health organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 2006; 44: 5719.
  • 33
    Dillner L,Dillner J International quality assurance of human papillomavirus testing. Cent Eur J Public Health 2008; 16: S18S20.
  • 34
    Herbert A,Arbyn M,Bergeron C. Why CIN3 and CIN2 should be distinguished on histological reports. Cytopathology 2008; 19: 634.